Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year.
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...
When given after organ-removal surgery, Keytruda brings patients battling advanced bladder cancers more time cance ...
If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for ...
The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.
In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.
Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on ...
Pharmaceutical Technology on MSN3d
FDA approves MSD’s KEYTRUDA as first-line MPM treatmentThe US FDA has granted approval for MSD’s KEYTRUDA regimen as a first-line treatment for malignant pleural mesothelioma (MPM) ...
Summit's therapy still remains years away from the market with a global late-stage trial being initiated in 2025, said J.P.
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...
Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback